Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Int Med Case Rep J ; 16: 209-213, 2023.
Article in English | MEDLINE | ID: covidwho-2260521

ABSTRACT

The COVID-19 epidemic is a major public health emergency that has affected every part of society worldwide, including neonates with different clinical presentations. It is essential to differentiate between increased incidence of complications related to this infection rather than an underlying congenital etiology. We report a rare case with atypical lung cystic lesions, diagnosed initially as congenital pulmonary airway malformation (CPAM) with management controversy but which turned out to be a COVID-19 viral pneumonia complication. Clinical tolerance and proper uses of radiological modalities are crucial to achieving better outcomes for patients. The literature is still missing reports on this topic and needs more studies to provide conclusive, evidence-based practice of this emerging neonatal viral infection. Vigilance in neonates with COVID-19 infection is highly recommended.

2.
Int J Mol Sci ; 22(21)2021 Oct 30.
Article in English | MEDLINE | ID: covidwho-1488618

ABSTRACT

The inflammatory response plays a central role in the complications of congenital pulmonary airway malformations (CPAM) and severe coronavirus disease 2019 (COVID-19). The aim of this study was to evaluate the transcriptional changes induced by SARS-CoV-2 exposure in pediatric MSCs derived from pediatric lung (MSCs-lung) and CPAM tissues (MSCs-CPAM) in order to elucidate potential pathways involved in SARS-CoV-2 infection in a condition of exacerbated inflammatory response. MSCs-lung and MSCs-CPAM do not express angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TRMPSS2). SARS-CoV-2 appears to be unable to replicate in MSCs-CPAM and MSCs-lung. MSCs-lung and MSCs-CPAM maintained the expression of stemness markers MSCs-lung show an inflammatory response (IL6, IL1B, CXCL8, and CXCL10), and the activation of Notch3 non-canonical pathway; this route appears silent in MSCs-CPAM, and cytokine genes expression is reduced. Decreased value of p21 in MSCs-lung suggested no cell cycle block, and cells did not undergo apoptosis. MSCs-lung appears to increase genes associated with immunomodulatory function but could contribute to inflammation, while MSCs-CPAM keeps stable or reduce the immunomodulatory receptors expression, but they also reduce their cytokines expression. These data indicated that, independently from their perilesional or cystic origin, the MSCs populations already present in a patient affected with CPAM are not permissive for SARS-CoV-2 entry, and they will not spread the disease in case of infection. Moreover, these MSCs will not undergo apoptosis when they come in contact with SARS-CoV-2; on the contrary, they maintain their staminality profile.


Subject(s)
Mesenchymal Stem Cells/metabolism , Respiratory System Abnormalities , SARS-CoV-2/physiology , Transcriptome , COVID-19/genetics , COVID-19/metabolism , COVID-19/pathology , Case-Control Studies , Cells, Cultured , Gene Expression Profiling , Host-Pathogen Interactions/genetics , Humans , Infant , Lung/abnormalities , Lung/metabolism , Lung/pathology , Male , Mesenchymal Stem Cells/pathology , Mesenchymal Stem Cells/virology , RNA-Seq , Respiratory System Abnormalities/genetics , Respiratory System Abnormalities/pathology , Respiratory System Abnormalities/virology
SELECTION OF CITATIONS
SEARCH DETAIL